682 related articles for article (PubMed ID: 7793078)
1. CTL escape viral variants. I. Generation and molecular characterization.
Lewicki H; Tishon A; Borrow P; Evans CF; Gairin JE; Hahn KM; Jewell DA; Wilson IA; Oldstone MB
Virology; 1995 Jun; 210(1):29-40. PubMed ID: 7793078
[TBL] [Abstract][Full Text] [Related]
2. CTL escape viral variants. II. Biologic activity in vivo.
Lewicki HA; Von Herrath MG; Evans CF; Whitton JL; Oldstone MB
Virology; 1995 Aug; 211(2):443-50. PubMed ID: 7645248
[TBL] [Abstract][Full Text] [Related]
3. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules.
Hudrisier D; Oldstone MB; Gairin JE
Virology; 1997 Jul; 234(1):62-73. PubMed ID: 9234947
[TBL] [Abstract][Full Text] [Related]
4. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection.
Oldstone MB; Lewicki H; Borrow P; Hudrisier D; Gairin JE
J Virol; 1995 Dec; 69(12):7423-9. PubMed ID: 7494247
[TBL] [Abstract][Full Text] [Related]
5. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants.
Byrne JA; Ahmed R; Oldstone MB
J Immunol; 1984 Jul; 133(1):433-9. PubMed ID: 6202788
[TBL] [Abstract][Full Text] [Related]
6. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
[TBL] [Abstract][Full Text] [Related]
7. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection.
van der Most RG; Sette A; Oseroff C; Alexander J; Murali-Krishna K; Lau LL; Southwood S; Sidney J; Chesnut RW; Matloubian M; Ahmed R
J Immunol; 1996 Dec; 157(12):5543-54. PubMed ID: 8955205
[TBL] [Abstract][Full Text] [Related]
8. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
9. Preferential usage of V alpha 4 and V beta 10 T cell receptor genes by lymphocytic choriomeningitis virus glycoprotein-specific H-2Db-restricted cytotoxic T cells.
Aebischer T; Oehen S; Hengartner H
Eur J Immunol; 1990 Mar; 20(3):523-31. PubMed ID: 2138558
[TBL] [Abstract][Full Text] [Related]
10. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition.
Sheil JM; Schell TD; Shepherd SE; Klimo GF; Kioschos JM; Paterson Y
Eur J Immunol; 1994 Sep; 24(9):2141-9. PubMed ID: 7522163
[TBL] [Abstract][Full Text] [Related]
11. Peptides control the gain and loss of allele specificity by mutated MHC class I molecules.
Hengel H; Burke K; Kyburz D; Zinkernagel RM; Koszinowski UH
J Immunol; 1995 May; 154(9):4557-64. PubMed ID: 7722309
[TBL] [Abstract][Full Text] [Related]
12. Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity.
Alexander-Miller MA; Burke K; Koszinowski UH; Hansen TH; Connolly JM
J Immunol; 1993 Jul; 151(1):1-10. PubMed ID: 8392095
[TBL] [Abstract][Full Text] [Related]
13. Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones.
Deckhut AM; Tevethia SS
J Immunol; 1992 May; 148(10):3012-20. PubMed ID: 1374447
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic T lymphocytes from the BALB/c-H-2dm2 mouse recognize the vesicular stomatitis virus glycoprotein and are restricted by class II MHC antigens.
Browning MJ; Huang AS; Reiss CS
J Immunol; 1990 Aug; 145(3):985-94. PubMed ID: 1695651
[TBL] [Abstract][Full Text] [Related]
15. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes.
Gairin JE; Mazarguil H; Hudrisier D; Oldstone MB
J Virol; 1995 Apr; 69(4):2297-305. PubMed ID: 7533855
[TBL] [Abstract][Full Text] [Related]
16. Competition between unrelated peptides recognized by H-2-Kd restricted T cells.
Pala P; Bodmer HC; Pemberton RM; Cerottini JC; Maryanski JL; Askonas BA
J Immunol; 1988 Oct; 141(7):2289-94. PubMed ID: 2459204
[TBL] [Abstract][Full Text] [Related]
17. Low-affinity cytotoxic T-lymphocytes require IFN-gamma to clear an acute viral infection.
Von Herrath MG; Coon B; Oldstone MB
Virology; 1997 Mar; 229(2):349-59. PubMed ID: 9126248
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes.
Bachmann MF; Lutz MB; Layton GT; Harris SJ; Fehr T; Rescigno M; Ricciardi-Castagnoli P
Eur J Immunol; 1996 Nov; 26(11):2595-600. PubMed ID: 8921944
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo.
Kyburz D; Speiser DE; Aebischer T; Hengartner H; Zinkernagel RM
J Immunol; 1993 Jun; 150(11):5051-8. PubMed ID: 7684417
[TBL] [Abstract][Full Text] [Related]
20. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
Uger RA; Barber BH
J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
